Educational overview · Approx. 4 min read · illustrative, not advice
Print this page. Ask every question in writing. The pattern of what a seller will and will not put in writing tells you more than any answer.
On money and structure
Ask: What is the total fee, and is any portion recurring, ever? Is there any revenue share, royalty, technology fee, brand fund, required purchase or transfer fee, now or under any future circumstance? What triggers any additional charge? What is the refund policy, in the contract, in writing? May I see the full agreement before I pay anything, including any deposit?
Ask: Is this a franchise under my state's law, and what is your basis for that position? A seller who answers with certainty about your state's law rather than referring you to your own counsel is overreaching. The correct answer sounds like an explanation of the structure plus an invitation to have your lawyer review it.
Atlas's answers: the license fee is one time, The license fee is one-time. It carries 0% of revenue and no ongoing partner fees. The figure is not published anywhere, by design — it is disclosed in full on the fit call, where it can be put next to what it covers instead of floating on its own., with no revenue share, no royalty and no ongoing partner fee. The agreement is available for review before payment. Ask Atlas to put this in writing: the refund and cancellation terms as written in the current license agreement, quoted verbatim We do not offer a view on whether the structure is a franchise in your state; ask your counsel.
On numbers and proof
Ask: Have you shown me any figure describing what I might earn? If yes, ask for the Franchise Disclosure Document and the Item 19 substantiation behind it. If they have no FDD and are still showing you numbers, you have learned everything you need to know, and the correct next step is to leave.
Ask: Are your testimonials real, named, consented people describing their own experience? May I contact them directly, chosen by me from a full list rather than selected by you? Are any of them compensated, and is that disclosed?
Ask: How many partners have you built, how many are still operating, and how many stopped? What happened to the ones who stopped? A seller who cannot or will not answer the third question has given you the answer.
Atlas's answers: we publish no earnings figures anywhere, by policy, because we have no FDD and therefore no substantiated basis. Where consented social proof belongs in our materials you will see , and it stays empty until a real named partner consents in writing. Ask Atlas to put this in writing: current count of builds delivered, count still operating, and the process by which a prospective partner may contact them
On what is actually delivered
Ask for the deliverable list, itemised, with dates. For each item ask three follow-ups: is it delivered configured, delivered as an account I must configure, or not included? Who performs the work? What is the remedy if it is late?
Ask: Which parts are on the business side and which require the clinical entity? Who supplies the clinical entity, and is it separately licensed? Do you employ clinicians or provide any medical service? A seller who is vague here is either confused about corporate practice of medicine or hoping you are.
Ask: Walk me through, live in your real systems, a member who signs up, pays, is declined by the clinician, and requests a refund. Sellers with a real build can do this in ten minutes. Sellers with a slide deck cannot do it at all.
On ownership and exit
Ask: In whose legal name are the domain, brand assets, ad accounts, payment processor, CRM and member data? Can I export all member data at any time, in a usable format, without permission? Do you retain any right to use my member list or my brand?
Ask: What survives if you cease operating tomorrow? Which of my systems stop working? Which relationships are mine directly versus routed through you? Can I sell my business, and does that require your consent?
Ask: Do you restrict what else I may sell, who I may buy from, or where I may operate? Is any geographic exclusivity offered, how is it enforced, and what is the remedy if it is breached? Note that a seller offering protected geography is offering a promise that only means something if there is an enforcement mechanism attached to it.
On risk and the uncomfortable ones
Ask: What is your position on the FDA proposal of April 30, 2026 regarding the 503B bulks list, and what happens to my supply arrangement under each outcome? A seller who does not know what you are referring to is not current in this category.
Ask: What happened to your buyers when compounding enforcement discretion ended in 2025? Ask: What is the single most common reason your builds underperform? Ask: Who should not buy this? Ask: What do you get wrong most often?
Ask: What are the three biggest risks to this business, in your own words? Then compare their answer to page thirteen of this document. A seller whose risk list is shorter than the one their own competitor published is either less informed than you now are, or less candid.
Finally, ask everything above in writing and keep the replies. The pattern of what a company will put in writing, and how fast, is the most reliable signal you will get. If a seller answers freely on a call and goes quiet when asked to confirm by email, that is the finding.
- Federal Register / US FDA (docket notice, June 26, 2026) — FDA proposed on April 30, 2026 to exclude semaglutide, tirzepatide and liraglutide from the 503B bulk drug substances list; comments due July 30, 2026. (source) [VERIFIED]
- Alston & Bird — Enforcement discretion for 503A compounding pharmacies ended April 22, 2025 and for 503B outsourcing facilities May 22, 2025. (source) [VERIFIED]
- Atlas Metabolic (statement of its own commercial terms and policy) — Atlas charges a one-time license fee with no royalty, revenue share or ongoing partner fee; makes the agreement available for review before payment; publishes no earnings figures because it has no FDD; and leaves empty until a real, named partner consents in writing. [VERIFIED]